The FDA approved mRESVIA, an mRNA vaccine by Moderna, for adults aged 60 years and older to prevent lower respiratory tract disease caused by RSV. This is the third RSV vaccine approved in the past year, following Arexvy from GSK and Abrysvo by Pfizer. mRESVIA is a single-dose vaccine that showed 83.7% efficacy against RSV in a phase 3 clinical trial with no serious safety concerns. It is the first non-COVID-19 mRNA vaccine to be approved. Moderna expects mRESVIA to be available in the US for the 2024-2025 respiratory virus season.
Source link
Moderna’s RSV Vaccine Approved by FDA
